SQLite Web: event_store.db

Update row 478274 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-22T03:03:32.063787+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:542572442ece078e","evidence_event_ids":["evt_105c2cbc7dc4"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1729214/0001171843-26-002595.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1729214/0001171843-26-002595.txt","company":"XORTX Therapeutics Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1729214/0001171843-26-002595.txt","article_chars":4716,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_4d3f28911ede191e","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1729214/0001171843-26-002595.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:05:37.142566+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1729214/0001171843-26-002595.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1729214/0001171843-26-002595.txt","source_event_id":"evt_105c2cbc7dc4","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"6-K","fp":"dbf66f272e132a99","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-06","2026-04-17","2026-04-20","2026-04-21","2026-04-22"],"entities":[{"asset_class":"equity","name":"XORTX Therapeutics Inc.","relevance":"high","symbol":"XRTX","type":"issuer"},{"asset_class":"exchange","name":"Nasdaq Stock Market LLC","relevance":"high","symbol":"","type":"regulator_exchange"},{"asset_class":"exchange","name":"Nasdaq Listing Qualifications Department","relevance":"high","symbol":"","type":"regulator_exchange_department"}],"event_type":"listing","information_gaps":["What the prior known state was (e.g., the specific date Nasdaq notified XORTX of noncompliance) is not included in the provided text.","The Form 6-K exhibit details beyond Exhibit 99.1 are not provided in the cleaned text (only that Exhibit 99.1 is listed).","No additional financial or operational guidance is disclosed in the provided text; the filing\u2019s financial implications are not explicitly stated."],"key_facts":["The filing is a Form 6-K for the month of April 2026.","XORTX received a letter of compliance from Nasdaq\u2019s Listing Qualifications Department related to Nasdaq Rule 5550(a)(2) (minimum bid price of US$1.00 per share).","To regain compliance, XORTX\u2019s common shares were required to trade at or above US$1.00 per share for at least 10 consecutive trading days.","XORTX implemented a 1-for-5 reverse split on April 6, 2026.","The minimum bid requirement was met on April 17, 2026.","XORTX received the compliance letter from Nasdaq on April 20, 2026.","As a result, the deficiency in the Minimum Bid Requirement has been cured."],"numeric_claims":[{"label":"reverse split ratio","value":"1-for-5"},{"label":"minimum bid price requirement (US$)","value":"1.00"},{"label":"consecutive trading days required","value":"10"},{"label":"reverse split date","value":"2026-04-06"},{"label":"date requirement met","value":"2026-04-17"},{"label":"date compliance letter received","value":"2026-04-20"}],"primary_claim":"Nasdaq issued XORTX a letter of compliance confirming the company cured its Nasdaq Rule 5550(a)(2) minimum bid price deficiency after meeting the $1.00 minimum bid requirement for 10 consecutive trading days.","relevance_score":0.72,"sentiment":"positive","source_quality":"high","summary":"XORTX Therapeutics Inc. filed a Form 6-K reporting that Nasdaq issued a compliance letter confirming the company regained compliance with the Nasdaq minimum bid price requirement. The deficiency was cured after a 1-for-5 reverse split on April 6, 2026 and the shares traded at or above $1.00 for at least 10 consecutive trading days by April 17, 2026.","topics":["Nasdaq minimum bid price compliance","Rule 5550(a)(2)","reverse stock split","Form 6-K","listing requirements"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 6-K \u00b7 XORTX Therapeutics Inc. \u00b7 Filed 20260421","ticker":"XRTX","tickers":["XRTX"],"title":"XRTX filed 6-K","url":"https://www.sec.gov/Archives/edgar/data/1729214/0001171843-26-002595.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel